Evolus, Inc. (LON:0K16)
14.58
+0.43 (3.00%)
At close: Jan 31, 2025
Evolus Revenue
Evolus had revenue of $69.39M USD in the quarter ending June 30, 2025, with 3.70% growth. This brings the company's revenue in the last twelve months to $277.94M, up 17.15% year-over-year. In the year 2024, Evolus had annual revenue of $266.27M with 31.76% growth.
Revenue (ttm)
$277.94M
Revenue Growth
+17.15%
P/S Ratio
1.80
Revenue / Employee
$837.17K
Employees
332
Market Cap
365.37M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 266.27M | 64.19M | 31.76% |
Dec 31, 2023 | 202.09M | 53.47M | 35.98% |
Dec 31, 2022 | 148.62M | 48.94M | 49.10% |
Dec 31, 2021 | 99.67M | 43.13M | 76.29% |
Dec 31, 2020 | 56.54M | 21.62M | 61.89% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Oxford Nanopore Technologies | 183.19M |
Evolus News
- 7 days ago - Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp - Business Wire
- 12 days ago - Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product - Business Wire
- 14 days ago - Insider Buying: Brady Stewart Acquires 30,000 Shares of Evolus Inc (EOLS) - GuruFocus
- 24 days ago - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 26 days ago - Evolus plunges after Q2 miss, guidance cut; Needham downgrades - Seeking Alpha
- 26 days ago - Evolus (EOLS) Q2 Revenue Rises 4% - The Motley Fool
- 27 days ago - Evolus outlines $700M 2028 revenue target and cost realignment amid market softness - Seeking Alpha
- 27 days ago - Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript - Seeking Alpha